Vicore Pharma: Time to execute on the phase 2b
Vicore Pharma reported its Q3'24 result with i) a cash position at SEK380.4m (excl. SEK882m capital increase), ii) EBIT SEK(60.1m), and iii) operating expenses at SEK61.3m. Moving into the Q4, the main priority will be to continue to activate clinical sites and enroll patients in the phase 2b ASPIRVicore Pharma Holding AB is a Sweden-based drug-development company. The Company's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The Company is a wholly owned subsidiary of Mintage Scientific AB.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.